Brief: CorMedix Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 25 (Reuters) - CorMedix Inc CRMD.O: CORMEDIX Q4 BASIC EPS USD 0.22 CORMEDIX Q4 NET INCOME USD 13.5 MILLION CORMEDIX Q4 OPERATING EXPENSES USD 17.1 MILLION CORMEDIX INC - TO COMMENCE PHASE 3 STUDY OF DEFENCATH IN Q2 2025 CORMEDIX INC - PRELIM NET REVENUE GUIDANCE FOR H1 2025 $50 MILLION - $60 MILLION Source text: ID:nGNX6Kw1Nk Further company coverage: CRMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CorMedix
See all newsBrief: Cormedix Announces FDA Acceptance For Priority Review Of Supplemental NDA For Rezzayo
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
CorMedix Inc. reports results for the quarter ended June 30 - Earnings Summary